Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. (Q38370866)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. (English)

1 reference

Europe PubMed Central

2 September 2017

1 reference

based on heuristic

inferred from title

Angela Dispenzieri

1

1 reference

Europe PubMed Central

2 September 2017

7

object named as

David Dingli

1 reference

Europe PubMed Central

2 September 2017

17

object named as

Robert A Kyle

1 reference

Europe PubMed Central

2 September 2017

5

object named as

Martha Q Lacy

1 reference

Europe PubMed Central

2 September 2017

Stephen J. Russell

14

object named as

Stephen J Russell

1 reference

Europe PubMed Central

2 September 2017

S. Vincent Rajkumar

16

object named as

S Vincent Rajkumar

1 reference

Europe PubMed Central

2 September 2017

2

object named as

Morie A Gertz

1 reference

Europe PubMed Central

2 September 2017

Suzanne R Hayman

10

object named as

Suzanne R Hayman

1 reference

Europe PubMed Central

2 September 2017

Steven R Zeldenrust

9

object named as

Steven Zeldenrust

1 reference

Europe PubMed Central

2 September 2017

Francis K Buadi

6

object named as

Francis K Buadi

1 reference

Europe PubMed Central

2 September 2017

4

object named as

Shaji K Kumar

1 reference

Europe PubMed Central

2 September 2017

15

object named as

Ronald S Go

1 reference

Europe PubMed Central

2 September 2017

Prashant Kapoor

11

object named as

Prashant Kapoor

1 reference

Europe PubMed Central

2 September 2017

13

object named as

Lisa Hwa

1 reference

Europe PubMed Central

2 September 2017

12

object named as

Martha Grogan

1 reference

Europe PubMed Central

2 September 2017

author name string

Amy Saenger

3

1 reference

Europe PubMed Central

2 September 2017

Nelson Leung

8

1 reference

Europe PubMed Central

2 September 2017

Allan Jaffe

18

1 reference

Europe PubMed Central

2 September 2017

publication date

2 April 2015

1 reference

Europe PubMed Central

2 September 2017

American Journal of Hematology

1 reference

Europe PubMed Central

2 September 2017

90

1 reference

Europe PubMed Central

2 September 2017

524-528

1 reference

Europe PubMed Central

2 September 2017

6

1 reference

Europe PubMed Central

2 September 2017

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

The IL-33/ST2 pathway: therapeutic target and novel biomarker

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Increased Soluble ST2 Predicts Long-term Mortality in Patients with Stable Coronary Artery Disease: Results from the Ludwigshafen Risk and Cardiovascular Health Study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Sciatic nerve injury related to hip replacement surgery: imaging detection by MR neurography despite susceptibility artifacts

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Emerging biomarkers in heart failure

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Interleukin family member ST2 and mortality in acute dyspnoea

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Interleukin receptor family member ST2 concentrations in patients following heart transplantation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24001

21 January 2018

Identifiers

10.1002/AJH.24001

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38370866&oldid=1739058976"